N-[(2S)-3-(1,3-benzothiazol-2-yl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-6-(hydroxymethyl)-3,3-dimethyl-2,4-dihydro-1H-quinoline-8-sulfonamide | 184039-55-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2S)-3-(1,3-benzothiazol-2-yl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-6-(hydroxymethyl)-3,3-dimethyl-2,4-dihydro-1H-quinoline-8-sulfonamide
• CAS: 184039-55-2
• 化学式: C₂₉H₃₇FN₄O₄S₂
• 分子量: 588.768
• InChiKey: YFEWXCNYXKGDJF-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  148
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-甲氧基乙氧基甲基氯 、 N-[(2S)-3-(1,3-benzothiazol-2-yl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-6-(hydroxymethyl)-3,3-dimethyl-2,4-dihydro-1H-quinoline-8-sulfonamide 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[(2S)-3-(1,3-benzothiazol-2-yl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-6-(2-methoxyethoxymethoxymethyl)-3,3-dimethyl-2,4-dihydro-1H-quinoline-8-sulfonamide
  参考文献：
  名称：

  the design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors

  摘要：

  The further optimisation of the novel lead compound CGH752 (Fig. 1) is described. By introducing various substituents into the 6-position of the 3,3-dimethyltetrahydroquinoline (DMTHQS) ring we have been able to favourably affect the in vitro and in vivo activity, and the pharmacokinetics of such compounds. One of the inhibitors synthesised (CGH1484) is bioavailable and shows efficacy in animal models of thrombosis. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00283-3
• 作为产物：
  描述：

  dimethylmalonic acid monochloride 在 palladium on activated charcoal 吡啶 、 sodium hydroxide 、 sodium tetrahydroborate 、 tetraphosphorus decasulfide 、 甲烷磺酸 、 pyridine-SO3 complex 、 TEA 、 potassium tert-butylate 、 氢气 、 phosphorus pentoxide 、 sodium cyanoborohydride 、 溶剂黄146 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 N-[(2S)-3-(1,3-benzothiazol-2-yl)-1-[4-(2-fluoroethyl)piperidin-1-yl]-1-oxopropan-2-yl]-6-(hydroxymethyl)-3,3-dimethyl-2,4-dihydro-1H-quinoline-8-sulfonamide
  参考文献：
  名称：

  the design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors

  摘要：

  The further optimisation of the novel lead compound CGH752 (Fig. 1) is described. By introducing various substituents into the 6-position of the 3,3-dimethyltetrahydroquinoline (DMTHQS) ring we have been able to favourably affect the in vitro and in vivo activity, and the pharmacokinetics of such compounds. One of the inhibitors synthesised (CGH1484) is bioavailable and shows efficacy in animal models of thrombosis. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00283-3

文献信息

• the design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors
  作者：Judy Hayler、Peter D Kane、Darren LeGrand、Florence Lugrin、Keith Menear、Richard Price、Mark Allen、Xiaoling Cockcroft、John Ambler、Keith Butler、Karren Dunnet、Andrew Mitchelson、Mark Talbot、Morris Tweed、Nicholas Wills

  DOI：10.1016/s0960-894x(00)00283-3

  日期：2000.7

  The further optimisation of the novel lead compound CGH752 (Fig. 1) is described. By introducing various substituents into the 6-position of the 3,3-dimethyltetrahydroquinoline (DMTHQS) ring we have been able to favourably affect the in vitro and in vivo activity, and the pharmacokinetics of such compounds. One of the inhibitors synthesised (CGH1484) is bioavailable and shows efficacy in animal models of thrombosis. (C) 2000 Elsevier Science Ltd. All rights reserved.